October 21, 2017 2:09 AM ET


Company Overview of Adamas Pharmaceuticals, Inc.

Company Overview

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company’s product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease. Its portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer’s disease. The company’s products under development include ADS-4101, a chrono-synchronous lacosamide therapy that has completed fir...

1900 Powell Street

Suite 750

Emeryville, CA 94608

United States

Founded in 2000

72 Employees





Key Executives for Adamas Pharmaceuticals, Inc.

Co-Founder, Chairman & CEO
Age: 53
Total Annual Compensation: $700.0K
Chief Medical Officer
Age: 48
Total Annual Compensation: $550.7K
Chief Business Officer, General Counsel, Chief Compliance Officer & Corporate Secretary
Age: 47
Total Annual Compensation: $328.5K
Compensation as of Fiscal Year 2016.

Adamas Pharmaceuticals, Inc. Key Developments

Adamas Pharmaceuticals, Inc. Announces Board Changes

Adamas Pharmaceuticals, Inc. announced the appointment of Mardi C. Dier, Chief Financial Officer of Portola Pharmaceuticals, Inc., to its Board of Directors. Ms. Dier will serve on the Audit Committee. In addition, Adamas announced that Richard H. Booth has retired from the Adamas Board, effective immediately.

Adamas Pharmaceuticals, Inc. Announces Management Changes

Adamas Pharmaceuticals, Inc. appointed Christopher B. Prentiss as Adamas's Chief Accounting Officer. Prior to joining Adamas, Mr. Prentiss was the Vice President, Finance and Controller at InterMune, Inc. As a result of this appointment, Alfred G. Merriweather, Adamas's Chief Financial Officer, has ceased to be Adamas's principal accounting officer. Mr. Prentiss will continue to report to Mr. Merriweather.

Adamas Pharmaceuticals, Inc. - Analyst/Investor Day

To provide an overview of the market opportunity and commercial plans for GOCOVRI™

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Adamas Pharmaceuticals, Inc., please visit www.adamaspharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.